September, 2009
- Exciton received authorization from Health Canada to proceed with Investigational Testing of the exSALT™ SD7 wound dressing.
August, 2009
- Exciton Technologies Receives FDA Approval to Market exSALT™ SD7 Wound Dressing.
At Exciton we design and develop advanced materials technologies based on the input from the industries we serve to engineer cost effective solutions that are applied to products you need.
Currently our valuable portfolio of patentable platform technologies is based on the antimicrobial properties of silver, which can be utilized in the wound care and disinfectant markets in the prevent infection and the spread of diseases.